XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 8 — SEGMENT INFORMATION

 

The Company views its operations and manages its business as one operating and reportable segment, which is the business of designing and developing innovative neurostimulation products. The Company’s focus centers around the treatment of various mental health conditions without the need for drugs or psychotherapy. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis. This decision-making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.

 

The Company’s CODM assesses financial performance and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.

 

The following table provides information about the Company’s one reportable segment and includes the reconciliation to consolidated net loss.

 

               
    Three Months Ended
September 30,		  
    2025     2024  
Total revenues   $ 18,149     $ 36,031  
Less:                
Cost of revenues (excluding amortization and depreciation)     3,948       12,694  
Research and development expense (excluding share-based compensation expense):                
Clinical trials     33,505       50,000  
Halo Project     128,935       94,418  
Desktop project     11,700       34,147  
Other research and development     52,380       -  
General and administrative expense and Salaries and benefits (excluding stock based compensation and amortization expense)     779,900       547,606  
Amortization     5,473       4,211  
Stock based compensation     1,082,790       1,539,169  
Professional fees     265,149       262,303  
Interest income, net     (2,288 )     (1,000 )
Equity in net (income) loss from equity method investees     -       (159 )
Other income     (67,032 )     (59,101 )
Segment net loss     (2,276,311 )     (2,448,257 )
                 
Reconciliation of net loss                
Adjustments and reconciling items     -       -  
Consolidated net loss   $ (2,276,311 )   $ (2,448,257 )
           
  

Nine Months Ended

September 30,

 
   2025   2024 
Total revenues  $129,752   $141,542 
Less:          
Cost of revenues (excluding amortization and depreciation)   40,344    29,097 
Research and development expense (excluding share-based compensation expense):          
Clinical trials   235,083    60,825 
Halo Project   517,506    316,194 
Desktop project   47,113    75,671 
Other research and development   58,880    952 
General and administrative expense and Salaries and benefits (excluding stock based compensation and amortization expense)   2,089,859    1,787,487 
Amortization   15,385    10,666 
Stock based compensation   2,291,734    2,008,801 
Professional fees   811,562    731,099 
Interest income, net   (8,081)   (1,370)
Equity in net (income) loss from equity method investees   1,048    (4,651)
Other income   (125,046)   (99,322)
Segment net loss   (5,845,635)   (4,773,907)
           
Reconciliation of net loss          
Adjustments and reconciling items   -    - 
Consolidated net loss  $(5,845,635)  $(4,773,907)